Skip to main content
. 2022 Mar 26;2022:8775591. doi: 10.1155/2022/8775591

Table 2.

Effect of hypoxia on MSC viability, proliferation, and clonogenicity.

Treatment conditions Types of stem cells The effect compared to normoxia (methods of analysis) Ref.
O2 concentration Time/passage
1% 2 d hBM-MSC Proliferation (DNA Quant-iT Picrogreen assay), clonogenicity (Giemsa staining), and metabolic activity (Vybrant assay) increased; HIF-1α downregulated (qRT-PCR), the proapoptotic genes: BAX, BCL-2, and CASP-3 downregulated (qRT-PCR) [57]
1% 2 d rBM-MSC The proliferation decreased (Trypan Blue staining, cell count) [80]
1% 7 d hBM-MSC Proliferation significantly reduced (MTS proliferation assay) [58]
1% 7 d hBM-MSC HIF-1α upregulated three-folds (qRT-PCR) [58]
1% 9 d hAD-MSC Proliferation increased 1.7-folds (Trypan Blue staining, cell count) [62]
1% 10 d hBM-MSC Proliferation (DNA Quant-iT Picrogreen assay) decreased, and metabolic activity increased (Vybrant assay), HIF-1α downregulated (qRT-PCR), the proapoptotic genes BCL-2 and CASP-3 downregulated, BAX upregulated (qRT-PCR) [57]
1% 14 d mBM-MSC Viability (MTT viability assay) and proliferation (BrdU cell proliferation assay) increased, the main metabolic regulators like Hk2 upregulated (sqRT-PCR), shift to anaerobic glycolysis, the Slc16a3 (MCT-4) gene upregulated under prolonged hypoxia (qRT-PCT), the MCT-4 level increased under prolonged hypoxia (WB) [68]
1% 14 d rBM-MSC Clonogenicity increased (crystal violet staining) [80]
1% 21 d hAD-MSC Cell aging reduced, telomeres longer 1.5-folds (qPCR) [62]
1% 21 d hBM-MSC A slowdown of cell cycle progression, accumulation in G1 phase under prolonged hypoxia (flow cytometry) [58]
1-3% 16 h hBM-MSC Viability and proliferation (flow cytometry) maintained, Akt signaling pathway activated (WB) [81]
1.5% 1 d hBM-MSC
hUCB-MSC
Proliferation increased (Trypan Blue staining, cell count) and the cell cycle faster progression (flow cytometry), HIF-1α increased (WB) [82]
1.5% 3 d hUC-MSC Proliferation decreased (Trypan Blue staining, cell count), LDHA, GLUT-1, and PDK-1 upregulated (RT-PCR), glutamate production decreased (HPLC), glucose consumption significantly increased (YSI 2700 analyzer) [69]
2% 2 d hBM-MSC Proliferation (DNA Quant-iT Picrogreen assay), clonogenicity (Giemsa staining), and viability (flow cytometry) increased [57]
2% 2 d hWJ-MSC Expression of the genes HIF1-α, HIF-2α, Notch2, and JAGGED1 increased (RT-PCR) [64]
2% 7 d hBM-MSC A high growth rate maintained even after confluency–multilayer formation (cell count, growth curve), HIF-2α upregulated (RT-PCR) [38]
2% 7 d hBM-MSC Clonogenicity increased (crystal violet staining) [63]
2% 12 d hBM-MSC Higher proliferation rate (Trypan Blue staining, cell count), the number of actively dividing cells significantly increased (PKH26 Red Fluorescent Cell Linker kit), the cellular division started earlier in the cell cycle (PKH26 staining, flow cytometry) [63]
2% 20 d hBM-MSC Clonogenicity (colony count from microscopic images) and doubling time (cell count and growth curve) maintained, cellular senescence reduced (β-galactosidase staining, histochemistry) [71]
2% Passages 2-7 hBM-MSC Higher cell number in each passage from 2 to 7 (Trypan Blue staining, cell count) [38]
2% 10 passages hWJ-MSC Faster growth rates and higher total cell number yielded (cell area count, image analysis), normal karyotype maintained (Giemsa staining) [64]
2% 64 d hBM-MSC Homogenous morphology of rapidly self-renewing cells maintained up to 52 d (microscopy analysis) [83]
2.5% 3 d hUC-MSC Proliferation increased (cell counting under a microscope), HIF-1α increased (WB), PDK-1, GLUT-1, and LDHA upregulated (RT-PCR), glutamate production diminished (HPLC), glucose consumption significantly increased (YSI 2700 SELECT analyzer) [69]
2.5% ∗ >3 d hUCB-MSC Cell viability (at 24 h and 2 d) increased (Trypan Blue staining, cell count, and MTT); proliferation (at 3 d) increased (Trypan Blue staining, cell count), CFU-F number in vitro significantly enhanced (Giemsa staining) [60]
2.5% ∗ >3 d hUCB-MSCs Cell metabolic activity (MTT), CFU-F number (Giemsa staining), and proliferation (at 2 and 3 d) (Trypan Blue staining, cell count) increased, doubling time reduced (at 2 and 3 d) (Trypan Blue staining, cell count), cell death inhibited (at 2 and 3 d) (microscope analysis) [84]
3% ~100 d
Passage 1
hBM-MSC Proliferative lifespan with additional 10 PD improved (flow cytometry), transcription of hypoxia-related the genes encoding VHL, HIF-1, PH-4, HYOU1, HIF1AN, HIG, and HIG unaltered (qPCR) [33]
3% Over 25 passages hBM-MSC Cell growth improved (Trypan Blue staining, cell count), population doublings increased (Trypan Blue staining, cell count), oxidative stress reactions (DHE, flow cytometry) and nuclear alterations such as damage of DNA, telomere shortening, and chromosomal abnormalities (DAPI, Q-FISH, Breast Aneusomy Multicolor Probe kit) limited, glycolysis increased (OCR/ECAR, F96 Flux analyzer) [32]
5% 2 d hBM-MSC Proliferation rate lowered (DNA Quant-iT Picrogreen assay), clonogenicity (Giemsa staining), and metabolic activity elevated (Vybrant assay) [57]
5% 3 d hUC-MSC Proliferation increased (Trypan Blue staining, cell count), LDHA, PDK-1, and GLUT-1 upregulation (RT-PCR) [69]
5% 4 d rBM-MSC Proliferation rate increased (flow cytometry) [85]
5% 4 d hBM-MSC Clonogenicity (crystal violet staining), proliferation (EDU Proliferation kit), and metabolic activity (Alamar Blue staining) increased [65]
5% 14 d hBM-MSC Clonogenicity decreased at primary cells and the passage 1 but increased at the passages 2 and 3 (crystal violet staining) [66]
5% 20 d hBM-MSC Colony formation significantly reduced (colony count from microscopic images), doubling time maintained (Trypan Blue staining, cell count, growth curve), cellular senescence reduced (β-galactosidase staining, histochemistry, blue stained cell count) [71]
5% Passage 1-10 hBM-MSC The number of population doublings increased (Trypan Blue staining, cell count), cellular senescence reduced (β-galactosidase staining, histochemistry, blue stained cell count) [72]

Hypoxic preconditioning in 2.5% O2 for 15 minutes, then reoxygenation at 21% O2 for 30 minutes, and again hypoxia preconditioning at 2.5% O2 for 3 days; d: day/days; h: human; m: mouse; r: rat; PD: population doublings; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; BrdU: 5-bromo tetrazolium inner salt-20-deoxyuridine; MTS: tetrazolium inner salt; WB: Western Blotting.